子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识（2025年版）
摘 要
近年来消除子宫颈癌的策略和政策发生很大变化，人乳头瘤病毒（HPV）相关疾病及其防控研究也有新进展，本文结合国内外研究最新文献，在2019年发表的共识基础上更新形成“子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识（2025年版）”，供临床医生、疾病预防控制专业人员和接种人员在防控子宫颈癌等HPV相关疾病时参考，为HPV疫苗的科学使用和发挥其最佳预防作用提供系统和全面的循证依据。
【关键词】人乳头瘤病毒；人乳头瘤病毒相关疾病；子宫颈癌；免疫预防；专家共识
前 言 人乳头瘤病毒（human papilloma virus，HPV）感染可导致女性和男性出现一系列疾病。大多数HPV感染是无症状的，可自行清除，但持续感染HPV可能导致疾病发生。根据HPV的致癌性，将HPV分为高危型（high-risk HPV，hrHPV）和低危型（low-risk HPV，lrHPV）［1-2］。hrHPV持续感染可引起癌前病变或癌症发生。在女性中，持续感染hrHPV可能导致宫颈上皮内瘤变（cervical intraepithelial neoplasia，CIN），如果不治疗可能发展为子宫颈癌［3］。无论男性和女性，hrHPV感染与头部、颈部、口咽和肛门生殖器等部位的癌症有关；lrHPV感染可引起肛门-生殖器疣（anogenital wart，AGW）和复发性呼吸道乳头状瘤病（recurrent respiratory papillomatosis，RRP）等疾病。 子宫颈癌是HPV感染所致疾病中疾病负担最重的疾病，是常见的癌症之一，也是全球妇女癌症相关死亡原因之一。国际癌症研究署（International Agency for Research on Cancer，IARC）和世界卫生组织（World Health Organization，WHO）公布的结果显示［4］，2022年全球子宫颈癌发病数为66万余例，死亡数接近35万例，在癌症发病率和死亡率中分别排第8位和第9位。中国的研究结果显示［5］，2022年全国子宫颈癌发病近15.1万例，死亡近5.6万例。全球中低收入国家子宫颈癌发病率几乎是高收入国家的两倍，死亡率几乎是高收入国家的三倍［6］。 子宫颈癌是一种可以预防的疾病，如果早发现并进行适当治疗，也可以治愈。2020年11月WHO发布《加速消除子宫颈癌公共卫生问题的全球战略》［6］，确定全球消除子宫颈癌的愿景，即全球子宫颈癌发病率下降到4/10万以下，要实现该目标必须在2030年达到“90-70-90”目标，即90%的女童在15岁之前全程接种HPV疫苗、70%的妇女在35岁之前接受高效检测方法的筛查并且到45岁再次筛查、90%的宫颈疾病确诊妇女接受规范治疗。2023年1月，为贯彻落实《“健康中国2030”规划纲要》和《中国妇女发展纲要（2021-2030年）》，中国积极响应WHO提出的“加速消除子宫颈癌全球战略”，为加快中国子宫颈癌消除进程，保护和增进广大妇女健康，国家卫生健康委等10个部门出台中国《加速消除宫颈癌行动计划（2023-2030年）》［7］。 2019年中华预防医学会疫苗与免疫分会发布了《子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识》。五年来，消除子宫颈癌的策略和政策发生了很大变化，2022年WHO发布新的HPV疫苗立场文件，HPV相关疾病及其防控等方面研究也有新进展，为此我们更新了《子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识》，供临床医生、疾病预防控制专业人员和接种人员在防控子宫颈癌等HPV相关疾病时参考，为HPV疫苗的科学使用和发挥其最佳预防作用提供系统和全面的循证依据。 1 病原学 1.1 HPV的发现和种属 1.1.1 HPV与子宫颈癌病因关联的发现 1976年zur Hausen［8-9］首次提出HPV与子宫颈癌发病相关的假说，1977年Laverty等［10］在电镜下观察到子宫颈癌活检组织中存在HPV病毒颗粒，随后越来越多的研究者开展HPV致癌机制和流行病学研究。1995年 IARC出版专著，声明有充足证据支持hrHPV感染是导致子宫颈癌及其癌前病变的主要病因［11］。 1.1.2 HPV种属 HPV属于乳头瘤病毒科，分为α、β、γ、Mu和Nu属，其中α属包括与子宫颈癌等恶性肿瘤发生相关的hrHPV，以及与良性黏膜病变和皮肤疣相关的lrHPV［12-13］。 1.2 HPV的结构及其功能 HPV是一种嗜上皮组织的无包膜双链环状DNA病毒，由病毒蛋白衣壳和核心单拷贝的病毒基因组DNA构成。病毒衣壳由主要衣壳蛋白L1和次要衣壳蛋白L2组成。L1蛋白具有型别特异性，根据编码L1蛋白的基因组序列，已鉴定出200多种HPV型别［13-14］，而L2蛋白在不同型别HPV中高度保守［15］。L1蛋白的五邻体结构具有明显的抗原性并且是免疫细胞清除HPV的主要攻击位点。目前上市的预防性HPV疫苗均以L1蛋白为靶抗原。L2蛋白能够诱发广泛交叉保护作用的中和抗体，是未来通用预防性疫苗的研究靶点。 HPV基因组由长控制区（long control region， LCR）、早期区和晚期区组成。LCR可调控早期和晚期蛋白表达；早期区负责编码E1、E2、E4、E5、E6和E7蛋白，其中E6和E7蛋白是关键致癌因子［11］；晚期区负责编码病毒的L1和L2衣壳蛋白。 1.3 HPV的理化特性 HPV是无包膜病毒，对外界的抵抗力相对较强，在干燥环境中可存活较长时间［16］。物理和化学因素的作用会影响其活性。温度100 ℃条件下可使HPV灭活［17］，高剂量紫外线C照射是有效的消毒方式［18］。强酸邻苯二甲醛、过氧化氢、次氯酸等高效消毒剂可以杀灭存活于体外的HPV［19-21］。 1.4 HPV的致病性 1.4.1 HPV型别和所致疾病 目前从人体中鉴定出约200种HPV型别［13］，不同HPV型别间L1基因的差异超过10%［22］。根据HPV感染部位，HPV分为皮肤型HPV和黏膜型HPV。根据致癌潜力，HPV分为hrHPV（包括HPV16、HPV18、HPV31、HPV33、HPV35、HPV39、HPV45、HPV51、HPV52、HPV56、HPV58、HPV59、HPV68等）和lrHPV（包括HPV6、HPV11等）。hrHPV持续感染可导致子宫颈、阴道、外阴、肛门、阴茎、头颈等部位的癌前病变，病变可最终发展为浸润性癌［23］。lrHPV感染可引起皮肤疣、AGW、RRP等良性疾病［23］。 1.4.2 HPV致病机制 HPV感染人体可分为两个不同的通路，即感染扩增通路和转化通路。在感染扩增通路中［12， 23］，病毒在人体内完成病毒复制的生命周期，目前研究多认为其不会引起癌变；在转化通路中，hrHPV基因整合进入人类基因组，E6和E7癌蛋白过度表达，进而引发癌症［24］。 1.4.3 HPV感染子宫颈的自然病程 绝大多数HPV感染为无症状的一过性感染，组织学上可表现为子宫颈低级别鳞状上皮内病变（low-grade squamous intraepithelial lesion of cervix， LSIL），即轻度CIN（CIN1）。大约50%的HPV感染可在6个月内被机体清除，约90%的HPV感染可在24个月内清除［25-28］。如果HPV持续感染，则可进展为高级别鳞状上皮内病变（high-grade squamous intraepithelial lesion， HSIL），包括部分中度CIN（CIN2）和重度CIN（CIN3）。系统综述显示，CIN1逆转、持续、进展为CIN2+、进展为CIN3+和进展为浸润癌的概率分别为60%、25%、11%、2%和0.03%［29］。随着CIN严重程度增加，逆转率降低，进展率升高。通常从HPV感染进展为子宫颈癌前病变的时间相对较短，约需5年；而从子宫颈癌前病变进展为浸润癌需要10~20年［30］。 1.5 免疫学 1.5.1 非特异性和特异性免疫反应 机体感染HPV后，在产生获得性免疫之前通过皮肤、黏膜组织屏障、固有免疫细胞（主要包括单核吞噬细胞、自然杀伤细胞等）和固有免疫分子［例如干扰素（interferon，IFN）-α、β、γ等］组成的非特异性免疫屏障对病毒感染产生天然的抵抗力［31］。 机体产生针对HPV的特异性免疫反应包括细胞免疫和抗体介导的体液免疫。HPV的清除和CIN病变的逆转需要有效的细胞毒性T细胞反应［32］，在自动消退的病变局部可观察到循环抗原特异性CD8和CD4 Th1细胞大量浸润［33］。HPV感染后机体可产生针对病毒L1蛋白的特异性抗体，但由于HPV感染仅存在于黏膜上皮层，不存在血源性感染，因此不会引起强烈的免疫反应［31］。人体自然感染HPV后，全身抗原特异性T细胞反应相对较弱，同时产生的抗体也增长缓慢，抗体效价和亲合力不高。然而预防性HPV疫苗接种能够有效诱导体液免疫，产生高滴度且持久的中和抗体［34］，发挥中和病毒的作用。 1.5.2 HPV感染和免疫逃逸 HPV基因表达和蛋白合成发生在基底层角质形成细胞，装配和成熟发生在鳞状上皮分化良好的细胞内，HPV这种特殊的生活周期可避免被免疫系统中的免疫细胞识别，不易激活机体的固有免疫反应，导致HPV持续感染［31］。此外，HPV感染可影响抗原递呈，逃避宿主的免疫防御。 1.6 HPV核酸和抗体检测 1.6.1 HPV核酸检测 hrHPV与子宫颈癌之间密切的病因学关联使得HPV检测成为一种有效的子宫颈癌筛查方法。WHO和许多国家推荐将HPV核酸检测技术作为子宫颈癌筛查的首选方法［35-37］，中国2021年发布的《宫颈癌筛查工作方案》也将HPV核酸检测纳入子宫颈癌初筛方法［38］。HPV核酸检测还被用于流行病学研究、HPV疫苗接种效力和效果评估、疫苗接种前后HPV感染率和型别变化监测等领域。 1.6.2 HPV抗体检测 HPV抗体检测方法主要包括ELISA、假病毒中和试验和竞争性Luminex免疫检测［39］。HPV抗体检测主要用于评估HPV疫苗诱导的抗体水平变化。以免疫原性为替代终点的临床试验为迭代疫苗与上一代疫苗共用型别的非劣效性比较，为不同特征人群（例如年龄、性别）和不同剂次接种程序的审批、免疫持久性评价等提供重要证据［40-41］。 目前尚未明确HPV疫苗预防疫苗覆盖型别相关癌前病变所需的最低抗体阈值，有研究显示即便抗体水平低于检测限，HPV疫苗对疫苗覆盖型别相关病变仍具有预防作用［42］，因此在临床试验中免疫学指标不能完全替代病毒学终点（HPV持续感染的发生）和组织学终点（例如癌前病变或癌症的发生）来评估疫苗的保护效力。加之目前尚无通用的HPV抗体检测方法可以准确测量真实的HPV中和抗体滴度，不同检测方法的结果不可直接比较［43］，因此HPV抗体检测主要用于对群体免疫水平监测，不推荐将其用于个体疫苗接种有效性的证明。 2 临床学 2.1 子宫颈上皮内病变和子宫颈癌 引起子宫颈上皮内病变和子宫颈癌的主要病因是hrHPV持续感染。子宫颈上皮内病变包括鳞状上皮内病变和腺上皮内病变，前者包括LSIL（CIN1）和HSIL（CIN2和CIN3），后者指子宫颈原位腺癌（adenoc arcinoma in situ，AIS），也称为高级别子宫颈腺上皮内瘤变；其中HSIL和AIS是子宫颈癌的癌前病变。不同型别的hrHPV的致癌风险不同，其中HPV16和HPV18的致癌风险最高，可导致40%~60%的癌前病变和70%~75%的子宫颈癌［44-45］。 子宫颈上皮内病变和早期宫颈癌患者多数无临床症状，部分可有分泌物异常或接触性出血等症状，常通过子宫颈癌筛查发现。中晚期子宫颈癌除了发生上述症状外，病灶累及的器官也可伴随相应的症状发生。 2.2 阴道上皮内病变和阴道癌 阴道上皮内病变与子宫颈上皮内病变一样，分为LSIL和HSIL。阴道LSIL指阴道上皮内瘤变（vaginal intraepithelial neoplasia， VaIN）1级，即LSIL/VaIN1；阴道HSIL包括VaIN2和VaIN3。VaIN发病率远远低于CIN，为0.2/10万~2.0/10万，VaIN占女性下生殖道上皮内病变的0.4%~1.0%［46］。VaIN1中HPV常呈游离状态，发展为高级别VaIN的风险低。高级别VaIN是阴道癌的癌前病变，需要治疗。与CIN3相比，VaIN3进展为浸润癌的可能性更小，所需时间更长。阴道癌占女性生殖道肿瘤的1%~4%，其中HPV16感染较常见。约40%的原发性阴道癌患者有全子宫切除病史，其中20%~30%是因为子宫颈癌前病变切除子宫［47］，规范化处理子宫颈和阴道壁病变共存是预防阴道癌发生的重要措施。 阴道上皮内病变和子宫颈上皮内病变一样，多数无临床症状，常由于子宫颈癌筛查异常在进一步检查中发现，临床症状和子宫颈上皮内病变的症状相似。 2.3 外阴上皮内病变和外阴癌 外阴鳞状上皮内病变（vulvar squamous intraepithelial lesion， VSIL）分为HPV相关性VSIL和非HPV依赖性外阴上皮内瘤变（vulvar intraepithelial neoplasia， VIN）［48］。HPV相关性VSIL包括外阴LSIL和外阴HSIL；非HPV依赖性VIN可分为分化型外阴上皮内瘤变（differentiated vulvar intraepithelial neoplasia，dVIN）、分化型外生性外阴上皮内病变和伴有分化改变的外阴棘皮。外阴HSIL和非HPV依赖性VIN是外阴鳞状细胞癌（vulvar squamous cell carcinoma，VSCC）的癌前病变。HPV相关性HSIL占外阴癌前病变的大多数（75%~85%），dVIN占外阴癌前病变的少数（ 2018年全球归因于HPV感染引起的其他癌症合计约12.4万例，占归因于HPV感染癌症新发病例总数的17.9%，包括肛门癌2.9万例、外阴癌1.1万例、阴道癌1.4万例、阴茎癌1.8万例、口咽癌4.2万例、口腔癌0.59万例和喉癌0.41万例，分别占相应癌症全球新发病例的88.0%、24.9%、78.0%、50.0%、30.8%、2.2%和2.4%［3］。研究显示在HPV感染所致其他癌症中，87.0%的肛门癌、72.6%的外阴癌、63.7%的阴道癌、70.2%的阴茎癌和84.9%的头颈部癌症（包括口咽癌、口腔癌和喉癌）归因于HPV16和HPV18感染；95.9%的肛门癌、87.1%的外阴癌、85.3%的阴道癌、84.6%的阴茎癌和89.7%的头颈部癌症归因于HPV6、HPV11、HPV16、HPV18、HPV31、HPV33、HPV45、HPV52和HPV58感染［67］。在子宫颈癌已得到良好控制的国家或地区，HPV感染引起的其他癌症负担逐渐凸显［68-70］。 （3）AGW： AGW是由lrHPV感染引起的较常见的性传播疾病之一，超过90%的AGW由HPV6和HPV11感染引起［71］。AGW具有高度传染性，复发率为30%~70% ［72］。与一般人群相比，AGW患者发生HPV相关癌症（包括肛门生殖器癌和头颈癌）的风险增加［73］。目前关于AGW的全球流行病学证据主要来自发达国家或地区。一项系统综述显示，2001-2012年全球AGW年发病率（包括新发和复发病例）在西班牙的160.0/10万至英国的289.0/10万之间，中位数为194.5/10万；年新发病率（不包括复发病例）在西班牙的118.0/10万至美国的205.0/10万之间，中位数为157.0/10万，其中男性和女性发病率中位数分别为137.0/10万和120.5/10万，发病高峰年龄分别为25~29岁和20~24岁［74］。在引入多价HPV疫苗后，部分欧美国家报道接种人群AGW发病率显著下降［75-78］。 5.4.2 预防AGW的保护效果 四价HPV疫苗（酿酒酵母）可有效预防AGW，接种不同剂疫苗的预防效果相当。RCT的Meta分析显示，3剂次四价HPV疫苗（酿酒酵母）在15~26岁年轻女性中预防AGW的保护效果为97%（95%CI：91%~99%）［262］。西班牙14~23岁女性接种1剂次、2剂次和3剂次四价HPV疫苗（酿酒酵母）后预防AGW的保护效果分别为75%（95%CI：44%~92%）、60%（95%CI：35%~78%）和74%（95%CI：68%~79%）［263］。 5.4.3 预防癌前病变的保护效果 HPV疫苗可有效预防子宫颈、外阴、阴道、肛门等部位癌前病变，越早接种保护效果越好，预防高级别病变的保护效果更优。 英国12~13岁接种双价HPV疫苗（昆虫细胞）的女性至20岁时，与未接种者相比预防CIN3+、CIN2+和CIN1的保护效果分别为89%、88%和79%。接种疫苗年龄越小，保护效果越好，在12~13岁和17岁接种者中预防CIN3+的保护效果分别为86%（95%CI：75%~92%）和51%（95%CI：28%~66%）［264］。 瑞典全国卫生保健登记系统显示，17岁之前开始接种四价HPV疫苗（酿酒酵母）对CIN2+的保护效果为75%［265］。与未接种者相比，接种≥1剂次、3剂次、2剂次和1剂次四价HPV疫苗（酿酒酵母）在丹麦≤16岁女性中预防CIN3+的保护效果分别为63%（95%CI：55%~70%）、63%（95%CI：55%~70%）、62%（95%CI：44%~78%）和62%（95%CI：2%~86%），预防CIN2+的保护效果分别为57%（95%CI：49%~64%）、57%（95%CI：49%~64%）、51%（95%CI：24%~68%）和66%（95%CI：13%~87%）［266］。澳大利亚接种1剂次、2剂次和3剂次四价HPV疫苗（酿酒酵母）预防CIN2+的保护效果分别为35%（95%CI：19%~48%）、39%（95%CI：28%~48%）和41%（95%CI：35%~46%），调整接种年龄后，接种1剂次和2剂次的保护效果与接种3剂次的保护效果相当［267］。日本20~29岁接种HPV疫苗的筛查女性与未接种者相比，预防CIN2+和CIN3+的保护效果分别为76%（95%CI：40%~90%）和91%（95%CI：58%~100%）［268］。日本另一项研究显示，HPV疫苗预防CIN1+、CIN2+和CIN3+的保护效果分别为58%（95%CI：42%~69%）、75%（95%CI：46%~88%）和81%（95%CI：-15%~97%）［269］。 丹麦80%的外阴HSIL与hrHPV感染相关［283-286］。一项回顾性分析纳入了2000-2017年美国18个癌症中心18~39岁患者外阴、阴道和肛门癌前病变数据，评估疫苗引入前后发病率的变化趋势，结果显示15~19岁、20~24岁和25~29岁女性VIN3发病率分别下降21.0%、11.2%和7.6%，15~29岁和30~39岁女性VaIN3发病率分别下降19.1%和5.6%［287］。 5.5.4 预防CIN和子宫颈癌的效用 美国HPV疫苗效用监测项目（HPV-IMPACT）数据显示，2008- 2016年18~19岁和20~24岁女性CIN2+发病率年均分别下降38.5%和14.9%［288］。美国另一项研究也显示，1999-2017年子宫颈癌发病率逐年下降［289］。澳大利亚实施HPV疫苗接种策略10年后效用研究显示，实施HPV疫苗接种后7年，\n \n 表3 HPV疫苗在临床试验中的一般反应发生率\n \n \n 疫苗通用名称\n 局部反应\n 全身反应\n \n \n 特殊注意事项\n \n \n 双价HPV疫苗 (毕赤酵母)\n 注射部位疼痛16.5%~ 92.9% [185,196,227,230,304,306,308,312,320,323-324,328-329]、\n 全身反应一般较轻 且具有自限性,包括\n 2.5%~35.2% [308.329]\n 罕见的超敏 反应,包括过\n 已观察到疫苗\n \n \n 双价HPV疫苗 (大肠杆菌)\n 发红2%~ 44.3% [184,195,227,230,304,306,308,312,320,323,324,328,329]\n 发热[329]、头痛、头晕、 肌痛、关节痛、胃肠\n 43.1%~49% [227.310.330]\n 敏性反应[330]\n 免疫应激相关\n \n \n 双价HPV疫苗 (昆虫细胞)\n 36.5% [185,196,227,230,304,306,308,312,320,323-324,328-329]\n 、腹痛)等[300]\n 69% [330]\n \n 适当的准备可 以将影响最小 化[330]。为避 免晕厥受伤, 疫苗受种者应 在接种HPV疫\n \n \n 四价HPV疫苗 (酿酒酵母)\n \n \n 28.8%~59.2%[330]\n \n \n \n \n 九价HPV疫苗 (酿酒酵母)\n \n \n \n \n 苗后留观30\n \n \n 九价HPV疫苗 (大肠埃希菌)\n \n \n 25.4%~40.9% [332-333]\n \n min[331]\n \n\n\n 5.7.2 上市后监测和研究 自HPV疫苗于2006年上市以来，部分国家依靠完善的疑似预防接种异常反应（adverse event following immunization，AEFI）监测系统，为HPV疫苗上市后真实世界大规模接种的AE积累了丰富数据，美国［334］、中国［335］、澳大利亚［336］、韩国［337］和意大利［338］的大量证据有力证实了HPV疫苗安全性。各国AEFI监测系统未发现新的或非预期安全性问题，监测结果与临床试验数据类似。HPV疫苗的局部反应主要为接种部位红肿、疼痛、硬结等，全身反应主要为发热、乏力、头痛、头晕等，多为轻中度症状，严重不良反应罕见。目前的证据不支持HPV疫苗接种与自身免疫性疾病［339］、不良妊娠结局［340］、吉兰-巴雷综合征［341］、慢性炎性脱髓鞘性多神经病、体位性心动过速综合征、复杂性区域疼痛综合征、慢性疲劳综合征［342］、原发性卵巢功能不全和不孕症［343］、死亡等罕见AE存在因果关系。全球HPV疫苗上市后监测未发现该疫苗存在安全性问题。 5.8 HPV疫苗成本效益 在实施HPV疫苗应用策略尤其是将HPV疫苗纳入国家免疫规划时，除了疫苗安全性、有效性等因素外，经济性也是需考虑的关键指标。疫苗卫生经济学评价是应用经济学方法比较疫苗的成本投入与效果、效益、效用等产出比。其中成本效用比常用于疫苗的卫生经济性比较，采用增量成本与增量效用的比值［344］分析增加一个质量调整寿命年（quality-adjusted life years，QALY）或挽回一个伤残调整寿命年（disability adjusted life year，DALY）所需的成本［345］。子宫颈癌等HPV相关疾病进展缓慢，接种HPV疫苗的收益经过数年至数十年才能显现［346］，因此通常采用基于HPV相关疾病自然史的数学模型模拟预测干预效果和成本［347］。2021年一项对195个国家HPV卫生经济学的Meta分析显示，全球2017年HPV疫苗接种的增量成本效用比为4 217美元/DALY，该结果支持各国将HPV疫苗纳入免疫规划［348］。 在HPV疫苗具体使用策略的评价方面，应用于不同接种对象的卫生经济学研究结果存在差异。 5.8.1 青少年女性接种 尽管不同研究和报告质量存在差异，不同HPV疫苗在年轻女孩中接种均具有成本效益［349］。 欧美等高收入国家对青少年女性HPV疫苗接种实施的卫生经济学研究显示［350］，双价HPV疫苗（昆虫细胞）、四价HPV疫苗（酿酒酵母）和九价HPV疫苗（酿酒酵母）在不同的接种覆盖率（33%~100%）情况下均表现出极具有成本效益或具有成本效益。 在资源有限的中低收入国家中，对青春期女孩提供HPV疫苗接种的卫生经济学评价结果显示通常具有成本效益［351-353］。2021年一项研究结果表明，与未接种疫苗相比，在4个不同类型国家（越南、印度、尼日利亚和乌干达）为9~14岁女孩接种HPV疫苗均符合成本效益［354］。2022年一项对印度、巴西、越南和老挝等多个国家的HPV疫苗卫生经济学评价结果表明［355］，接种HPV疫苗具有成本效益，结合子宫颈癌筛查甚至可以节省成本。2021年对拉丁美洲国家开展的24项HPV疫苗卫生经济学研究进行Meta分析显示，拉丁美洲国家女孩接种HPV疫苗均可节省成本或具有成本效益［356］。 中国女性接种HPV疫苗卫生经济学评价也表明，12~25岁女性接种各类HPV疫苗均具有成本效益，结合筛查策略更具有成本效益［357］。2021年对中国开展的14项HPV疫苗接种卫生经济学系统评价研究显示，青少年女性接种各类HPV疫苗均具有成本效益，若结合扩大子宫颈癌筛查，同时推出低价国产HPV疫苗，则可以进一步提升卫生经济学价值［358］。2022年一项研究结果显示，在1倍人均GDP的意愿支付阈值下16~26岁女性接种HPV疫苗均具有成本效益［359］；9~14岁目标人群接种双价HPV疫苗在纳入评价的31个省份中均具有成本效益［360］；另一项针对双价HPV疫苗的研究［361］分析了64种不同策略，结果显示将筛查和疫苗接种相结合的策略更具有成本效益。 5.8.2 大龄女性接种 大年龄组女性接种HPV疫苗评价结果显示成本效益暂不明确，由于HPV疫苗对已经发生的感染无清除作用，在HPV相关癌症防控中的获益有限［362］。 2020年美国开展的关于大年龄组女性接种九价HPV疫苗（酿酒酵母）的研究显示，30岁、40岁和45岁HPV疫苗接种每获得1 QALY需要分别投入1.24万美元、3.82万美元和4.63万美元，即随着接种年龄的增加，疫苗接种产生相对较小的健康效益和相对较差的成本效益［363］。2021年美国的一项研究表明，为30~45岁成年女性接种四价HPV疫苗（酿酒酵母）或九价HPV疫苗（酿酒酵母）不太可能符合成本效益［364］。 2016年中国评价结果显示，农村女性23岁之前和城市女性25岁之前接种双价HPV疫苗具有成本效益，25岁以后接种虽然仍具有保护效果，但成本效益下降至阈值以下［365］。2021年中国一项系统评价也表明，各价HPV疫苗在大龄女性中接种的经济性存在着争议，但接种HPV疫苗合并进行子宫颈癌筛查在无HPV感染史女性当中更具有经济性［366］。中国成年女性HPV感染率与国外成年女性存在差异，建议进一步研究中国成年女性HPV感染和其癌前病变的自然史，补充和完善大龄女性接种HPV疫苗的卫生经济学证据［367］。 5.8.3 男性接种 一些国家已经将男性纳入HPV疫苗推荐对象，多数研究认为对青少年和年轻成年男性以及重点人群（如MSM）接种HPV疫苗具有成本效益，大龄男性人群接种的卫生经济学意义还需要进一步评估。 2021年一篇对9项男性接种HPV疫苗卫生经济学评价的系统综述显示，其中4项研究结论显示男性纳入接种方案符合成本效益，另有4项研究发现只有在特定条件下才具有成本效益，总体结论是当前将HPV疫苗推广到男性的成本效益证据很少，在采取这一战略之前各国需进行具体情况的成本效益分析［368］。 中国尚缺乏HPV疫苗用于男性的卫生经济学研究，建议尽快对MSM等重点男性人群接种HPV疫苗的成本效益、影响因素等进行评价，积累相关研究证据。 5.8.4 1剂次或2剂次接种策略评价 既往HPV疫苗普遍采用3剂次免疫策略，采用更少剂次的HPV疫苗接种策略可节省疫苗和接种成本，并可能提高依从性和接种率，多篇研究证实了2剂次HPV疫苗接种策略符合成本效益，但关于1剂次接种的经济学评价较少。 韩国一项研究表明，12岁女孩接种2剂次HPV疫苗是一种具有成本效益的选择，接种四价HPV疫苗（酿酒酵母）和双价HPV疫苗（昆虫细胞）均能节省成本。一项对越南、印度、尼日利亚和乌干达人群的模型研究表明，9~14岁女童接种2剂次HPV疫苗是最有效和最具有成本效益的策略［369］。2022年英国一项研究比较了1剂次与2剂次九价HPV疫苗（酿酒酵母）接种策略，认为采用13~14岁女孩和男孩接种1剂次导致出现更多HPV相关疾病，加重疾病负担，与2剂次接种方案相比成本效益偏低［370］。 在评估HPV疫苗的成本效益时很大程度上会受到疫苗价格、实施成本、HPV患病率、疫苗剂次数、是否结合筛查等参数的影响。因此，不同国家和地区在评估HPV疫苗成本效益或参考现有的文献进行评估时需考虑上述因素在本地区的实际情况［371］。 因此，从卫生经济学角度，实施HPV疫苗接种策略首先推荐适龄青少年女性接种，其次建议对男孩、MSM等人群进行疫苗接种。同时结合疫苗供应情况，选择采用2剂次策略和不同价次HPV疫苗。此外，需要继续关注HPV感染和子宫颈癌发病分布特征，建议通过Meta分析量化不同HPV疫苗的成本效益研究结果，提供更多可靠的经济学评价证据。 6 WHO有关HPV疫苗接种建议和全球接种进展 6.1 2022年WHO立场文件建议［176］ 2022年WHO立场文件建议将HPV疫苗纳入所有国家免疫规划，到2030年90%的女孩在15岁之前完成HPV疫苗接种。在女孩发生性行为之前对其进行接种将获得最佳的预防效果。目前所有获批HPV疫苗均具有良好的安全性和有效性。 6.1.1 疫苗接种与其他预防措施相结合 将HPV疫苗作为预防子宫颈癌和由HPV引起的其他疾病的协调和全面战略的一部分，该战略包括行为教育、筛查、诊断和治疗相关信息。HPV疫苗接种是一种一级预防干预措施，接种疫苗后仍需进行筛查。不应因其他相关干预措施无法同时实施而推迟将HPV疫苗引入免疫规划。接种HPV疫苗之前没有必要筛查HPV或HIV感染。 6.1.2 目标接种人群 WHO建议将9~14岁未发生性行为的女孩作为首要接种对象，在将HPV疫苗引入免疫规划之初应优先保证该人群高接种率。在引入HPV疫苗时，对9~18岁多个年龄组女孩进行免疫接种，将获得比单一年龄组更快更高的人群收益。只有在可行且负担得起、不占用首要接种对象或有效子宫颈癌筛查投入资源的前提下，才推荐对次要接种对象（如≥15岁女性、男孩、年长男性或MSM）进行接种。 6.1.3 接种程序 ①2剂次接种程序：建议对满9岁的首要接种对象和HPV疫苗批准范围内所有年长人群采用两剂次接种程序，2剂次之间间隔至少6个月。出于免疫规划和效率方面的考虑，推荐采用间隔12个月的程序，2剂次之间不设最大接种间隔，可间隔3年或5年。 ②1剂次接种程序：作为一种超说明书接种方案，1剂次接种程序可用于9~20岁女孩和男孩。 ③免疫功能低下人群接种程序：已知免疫功能低下或HIV感染者（无论年龄或抗反转录病毒治疗状况如何）应至少接种2剂次HPV疫苗（至少间隔6个月），并在可能的情况下接种3剂次。 6.1.4 疫苗选择 现有证据表明从公共卫生学角度看，所有目前批准的双价、四价和九价HPV疫苗在预防主要由HPV16和HPV18感染引起的子宫颈癌前病变和癌症方面具有相当的免疫原性、效力和效果。在选择HPV疫苗纳入国家免疫规划时，需评估当地目前与HPV相关的公共卫生问题（子宫颈癌、其他HPV相关癌症和生殖器疣）的规模、批准的HPV疫苗使用人群范围、产品特征例如单剂次疫苗效力数据、疫苗价格、免疫规划情况等。对于单剂次接种方案，建议选择有效力或免疫桥接数据的HPV疫苗。 6.1.5 特殊人群的疫苗接种 建议将免疫功能低下的妇女和男性（包括HIV感染者、遭受过性虐待的儿童和青少年等罹患HPV相关疾病风险较高者）作为公共卫生规划的一部分优先考虑接种HPV疫苗。对旅行者和卫生工作者，遵循一般人群的建议接种疫苗。 6.1.6 与其他疫苗同时接种 HPV疫苗可通过不同的注射器和不同的注射部位与其他非活性疫苗和减毒活疫苗同时接种。需考虑同时进行1剂次破伤风白喉联合疫苗加强接种，以提高免疫规划效率。 6.1.7 HPV疫苗互换使用 同一接种对象使用多剂次接种程序时，尽量选择相同的HPV疫苗。当之前选择的疫苗未知或无法获得时，可接种任何HPV疫苗以完成建议的程序。 6.2 全球HPV疫苗接种策略和进展 截至2025年4月7日统计显示［372-373］，在WHO 194个成员国家和地区中，147个国家和地区将HPV疫苗全部纳入免疫规划，2个国家和地区部分纳入免疫规划。在纳入免疫规划国家和地区中，接种目标人群仅包括女性有73个、包括女性和男性有76个；实施接种机构为医疗机构、学校、医疗机构和学校接种、因地区或省而异、不详分别有29个、81个、18个、2个、19个；采用1剂次、2剂次免疫程序分别有68个、77个（其中2剂次之间间隔6个月、12个月分别有73个、4个），免疫程序不详4个。 2023年WHO各区域HPV疫苗接种率在不同人群中差异较大［374-375］，将HPV疫苗纳入国家免疫规划的133个国家和地区中，推荐接种的所有女性和男性人群HPV疫苗第1剂次接种率和全程接种率（指按照免疫程序完成最后1剂次的接种率）分别为62%和52%；WHO非洲区、东地中海区、欧洲区、美洲区、东南亚区和西太平洋区HPV疫苗第1剂次接种率分别为62%、57%、62%、57%、58%和70%，全程接种率分别为52%、44%、57%、47%、44%和55%；在高收入水平国家中推荐接种的女性人群第1剂次接种率和全程接种率分别为56%和47%，在中高收入水平国家中分别为31%和20%，在中低收入水平国家中分别为16%和13%，在低收入水平国家中分别为30%和20%。 7 中国HPV疫苗使用 接种单位应遵照《中华人民共和国疫苗管理法》［374］和《预防接种工作规范》［375］相关要求，按照当地HPV疫苗接种方案、疫苗说明书［158-163］规定和“知情同意”原则，科学告知受种者或其监护人后，为受种者及时提供疫苗接种。HPV疫苗的接种对象、接种程序、接种剂量、接种途径和接种禁忌［158-163］见表4。 8 HPV相关疾病防控主要知识信息 HPV相关疾病防控主要知识信息包括病毒学、临床学、流行病学、疫苗学和消除子宫颈癌策略等五个部分，主要依据循证方法梳理得出，可作为科学传播子宫颈癌相关防控知识的基础。 8.1 病毒相关信息 8.1.1 HPV是感染生殖道常见的病毒之一。感染后可导致男性和女性出现一系列疾病，包括可能发展为癌症。 8.1.2 根据诱发癌症的可能性将HPV分为hrHPV和lrHPV。hrHPV可导致癌症的发生，常见的是子宫颈癌；lrHPV可导致良性皮肤和黏膜肿瘤，常见的是AGW。 8.1.3 大多数HPV感染是无症状的，可自行缓解，但持续感染HPV可能引发疾病。在女性中，持续感染hrHPV可能导致CIN，甚至发展为子宫颈癌［376］。 8.1.4 目前有12种型别的hrHPV可导致人类癌症，包括HPV16、HPV18、HPV31、HPV33、HPV35、HPV39、HPV45、HPV51、HPV52、HPV56、HPV58和HPV59。致癌风险因型别而异，其中HPV16导致子宫颈癌最多［2］。全球72%的子宫颈癌病例由HPV16和HPV18感染所导致［3］。HPV68被归类为可能致癌。 8.1.5 HPV6和HPV11导致的AGW较常见。虽然多种lrHPV可导致AGW，但以HPV6和HPV11为主，占所有病例的90%。 8.2 临床学相关信息 8.2.1 在HPV感染导致的癌症中子宫颈癌占80%［3］。HPV持续感染还与肛门鳞状细胞癌、外阴癌、阴道癌、阴茎癌、口咽癌、口腔癌和喉癌发生有关［376］。 8.2.2 hrHPV持续感染（通常为6个月）［377］是导致子宫颈癌的主要原因［378］。从感染HPV到发展为浸润性癌通常需要15~20年或更长时间［378-379］。这期间可以通过筛查及时发现并早期治疗癌前病变，有效防控进一步发展为子宫颈癌。 8.2.3 lrHPV引起的病变大多是自限性的。lrHPV还引起扁平疣、寻常疣、掌跖疣等，还有引起RRP和疣状表皮发育不良的报道［380］。 8.3 流行病学相关信息 8.3.1 子宫颈癌是女性第四大常见癌症［381］，全球每年新发子宫颈癌病例约66万例，死亡约35万例。国家或地区间发病率和死亡率不平衡，至少相差10倍。 8.3.2 中国子宫颈癌发病率和死亡率均呈现上升趋势［5］，2022年中国子宫颈癌估算病例数为15.07万例，死亡数为5.57万例；标化发病率为13.83/10万［5，94-101］，标化死亡率为4.54/10万［5，94-101］。 8.3.3 hrHPV持续感染是导致子宫颈癌的最主要危险因素［59-60］，吸烟、多性伴、合并感染、HIV感染、营养不良、遗传、长期口服避孕药等也是高风险患病因素［382-383］。 8.3.4 超过70%的性活跃女性和男性在生命中的某个时刻被感染HPV，有些人可能不止一次被感染［383］。 8.3.5 全球hrHPV感染率为10.4%［384］，在一些发展中国家可能高达36.5%［382］。在子宫颈细胞学异常的女性中，hrHPV感染率近70%［385］。中国子宫颈细胞学正常女性中HPV感染率为11.0%；子宫颈鳞癌患者中hrHPV感染率为97.6%，其中HPV16感染常见（76.6%），其次为HPV18感染（7.9%）［384］。 8.3.6 全球归因于HPV感染引起的非宫颈部位癌症合计约12.4万例，占归因于HPV感染癌症新发病例总数的17.9%［3］。2016年中国由HPV感染引起的非宫颈部位肿瘤新发病例合计约1.2万例，死亡病例共0.61万例，其中74.32%的女性病例和72.78%的男性病例发生在60岁以后［104］。 8.3.7 在感染HIV的妇女中，子宫颈癌是一种常见的癌症。感染HIV的女性持续感染HPV的风险较HIV呈阴性的女性高数倍，患子宫颈癌的可能性是后者的6倍［153］，并且更有可能在较年轻的时候患子宫颈癌［386-387］。 8.4 疫苗接种相关信息 8.4.1 目前中国批准使用的HPV疫苗共有6种［158-163］，包括国产双价HPV疫苗2种、九价HPV疫苗1种以及进口双价、四价、九价HPV疫苗各1种。 8.4.2 目前中国HPV疫苗批准适用人群起始年龄均为9岁，上限年龄因不同企业产品而有差异。首要接种目标人群为9~14岁女孩。接种年龄越小，接种HPV疫苗的获益越大［388-390］。 8.4.3 接种HPV疫苗和子宫颈癌筛查相结合可以最大限度地预防子宫颈癌，广泛接种HPV疫苗有可能将全球子宫颈癌发病率降低90%以上［290， 293］。 8.4.4 HPV疫苗的长期保护效力随着疫苗使用的年限延长而不断获得验证。基于目前已有的数据，HPV疫苗表现出较好的长期保护效力，最长的持久性保护效力超过10年，且没有提示需要加强接种的证据［228， 249］。 8.4.5 HPV疫苗在上市前临床试验和上市后应用中表现出良好的安全性。与其他疫苗类似，HPV疫苗接种后不良反应以局部反应为主，多为轻中度，严重不良反应罕见［336， 391-393］。 8.4.6 免疫功能异常人群接种HPV疫苗后也可产生相应的免疫反应，并有一定保护效果［197］。 8.4.7 对疫苗的活性成分或任何辅料成分有超敏反应者禁止接种HPV疫苗，或者注射后有超敏反应症状者，不应再次接种［158-163］。 8.4.8 WHO不建议孕妇接种HPV疫苗，虽然研究显示未发现接种HPV疫苗对妊娠结局有任何特定的安全问题［394］。哺乳期妇女接种HPV疫苗不影响母乳喂养安全。 8.4.9 WHO建议HPV疫苗可以与其他非活性疫苗和减毒活疫苗联合接种，但要使用不同的注射器在不同的注射部位接种。 8.4.10 接种HPV疫苗可以产生群体免疫。如果HPV疫苗接种覆盖率很高，那么将会通过群体免疫方式使未接种疫苗的个人得到保护，从而进一步增强对人群的保护效果［77］。 8.5 消除子宫颈癌信息 8.5.1 消除是指在确定地理区域内将传染病新发病例减少到零（或非常低的水平）［395］；同时需要继续采取措施以防止重新建立传播。目前WHO消除子宫颈癌的目标是将子宫颈癌发病率降到4/10万以下［6］。 8.5.2 消除子宫颈癌的目标是可以实现的。模型研究显示［293］，仅女孩接种HPV疫苗可将中低收入和加勒比国家年龄标准化子宫颈癌发病率从19.8/10万降低到2.1/10万；增加两次筛查可将发病率降低至0.7/10万。 8.5.3 采取消除子宫颈癌策略具有重要公共卫生意义［6］。子宫颈癌是一种可以预防的疾病，消除子宫颈癌体现全球的卫生公平。作为一种公共卫生问题，为取得消除子宫颈癌的最佳效果，必须将措施扩大到国家级，同时采取紧急和坚决的行动来推广和持续实施循证干预措施。 8.5.4 消除子宫颈癌全球战略需要加强多方面努力，包括国际和地方领导人的政治支持、跨部门伙伴之间的协调合作、对公平获得全民健康覆盖的广泛支持、有效的资源调动、加强卫生系统和在各级大力促进健康。 8.5.5 WHO提出的实现消除子宫颈癌目标为在2030年达到“90-70-90”目标，即90%的女孩在15岁之前全程接种HPV疫苗、70%的妇女在35岁之前接受高效检测方法的筛查且在45岁再次筛查、90%的宫颈疾病确诊妇女接受规范治疗［6］。 8.5.6 实现90%HPV疫苗接种覆盖率的战略行动包括疫苗保障、接种广覆盖、社会动员和创新［6］，即确保有充足和可负担得起的HPV疫苗、高疫苗质量和扩大疫苗接种覆盖率、加强宣传和社会动员、开展创新和提高疫苗接种效率。 8.5.7 实现70%的癌前病变筛查覆盖率的战略行动包括获得筛查和治疗服务、基本卫生制度、适宜的方法、技术和设备、能力和质量［6］，即了解获得服务的障碍并为获得服务创造有利的环境、将筛查和治疗服务纳入初级保健方案、推广“筛查和治疗”方法、确保供应可负担得起的且质量有保证的高效检测和治疗设备、加强实验室能力和质量保证。 8.5.8 实现为90%的子宫颈癌病例提供治疗和护理的战略行动包括具有治疗护理技术指南、转诊流程和机制、病理学诊断能力、手术能力、放疗化疗服务等，即执行子宫颈癌管理指南、在整个医疗体系建立转诊途径和以人为本的联系机制、加强病理学服务、扩大手术能力、增加获取放疗和化疗服务机会、加强并融合姑息治疗服务、优化整个连续医疗服务过程中卫生人力的能力、减少癌症污名化、为提高幸存者的生活质量以及应对其面临的精神卫生和性健康挑战提供全面支持。 8.5.9 到2030年中国要实现的加速消除子宫颈癌主要目标包括持续推进适龄女孩HPV疫苗接种试点工作、适龄妇女子宫颈癌筛查率达到70%、子宫颈癌和癌前病变患者治疗率达到90%［7］。 9 HPV相关疾病防控待研究的问题 9.1 HPV感染基础研究 9.1.1 HPV持续感染机制研究 大多数HPV感染是无症状的，可自行清除，持续感染HPV可能导致疾病。研究显示，持续感染最终导致癌症的发生，其影响因素除包括hrHPV因素外，还包括微生物、遗传、环境因素、其他个体特征等因素［396-397］，明确其他因素对HPV持续感染并致癌的贡献，对于推荐极优先接种疫苗人群和极优先筛查人群具有指导意义。 9.1.2 HPV在不同组织器官致癌机制研究 子宫颈癌中约99%与生殖器感染hrHPV有关［398］。但hrHPV感染导致肛门癌（约90%）、外阴癌和阴道癌（约40%）、口咽癌（30%~60%）［399］等其他器官癌症的比例存在差异，其原因值得深入研究。 9.1.3 HPV感染引起的自然免疫作用研究 HPV持续感染导致癌症发生的因果关联明确。但是自然感染产生抗体水平较低，自然感染产生的免疫对预防再次感染的作用研究结果不一致［400-402］，需进一步深入研究。 9.1.4 连续性检测HPV结果与子宫颈癌发展的相关性研究 连续检测HPV结果存在两个主要未解决问题［400］，一是个体HPV感染自然史有不确定性，例如重复检测无法检测到HPV感染是否真正清除？二是同型阳性结果是新感染还是既往感染？ 9.1.5 HPV抗体检测方法标准化研究 HPV抗体检测手段有限，缺乏通用、便捷、快速、准确的检测方法来测定中和抗体滴度［43］，需研究更理想的检测方法以提高抗体检测可及性。 9.2 子宫颈癌及其他HPV相关疾病流行病学研究 9.2.1 研究制定中国消除子宫颈癌的监测、评估框架和指标 “如果没有一个强有力的框架和工具，消除子宫颈癌的行动就无法推进”［35］。因此，为实现消除子宫颈癌最终目标和2030年的“90-70-90”目标［6］，需研究制定中国消除子宫颈癌的监测和评估框架，包括HPV流行率、疫苗接种率、筛查覆盖率以及子宫颈癌发病率、死亡率、过早死亡率、存活率等监测指标，并明确各项指标的元数据（指标名称、分类范围、定义、计算方法等）。 9.2.2 研究评估中国已有的报告系统能否满足中国消除子宫颈癌需求 中国目前还没有子宫颈癌专项监测系统，发病和死亡数据来自肿瘤登记和死因登记报告、中国成人慢性病与营养监测［403-404］，这些系统各有优势和局限性，需评估其是否满足消除子宫颈癌工作需求，并据此完善相应监测系统。 9.2.3 研究制定中国尚未满足消除子宫颈癌相关指标的监测、调查和研究方案 参考《世界卫生组织加速消除子宫颈癌公共卫生问题的全球战略执行情况监测框架》［405］，完善中国尚未满足一级、二级和三级预防子宫颈癌工作需要的监测和调查相关研究方案，以保证数据的可用性、可比性和精细度。 9.2.4 开展不同区域子宫颈癌流行特征、疾病负担和影响因素研究 证据是制定规划和干预措施的基础，目前可了解国家级子宫颈癌发病和死亡数据［403］，但缺乏省级和更小范围的系统研究。中国各地社会因素和自然因素差别较大，需开展更精细的相关研究作为证据来支持［403］。 9.2.5 开展HPV感染所致其他癌症和良性疾病的系统研究 HPV感染不仅导致子宫颈癌发生，还引起其他癌症［406］，lrHPV感染也引起AGW等良性疾病［407］。现有相关研究多为估算数据或样本有限的研究［408］，需系统开展相关研究，为干预和评估提供基础数据支持。 9.3 子宫颈癌筛查和治疗研究 9.3.1 开展筛查和规范性治疗实施工作的本底调查 2030年适龄女性子宫颈癌筛查率要达到70%、子宫颈疾病确诊妇女接受规范治疗率要达到90%［6］。但是，中国有关筛查的本底数据有限，规范治疗的数据更是缺乏［409］。开展本底调查是实现目标和推动措施落实的基础。 9.3.2 开展筛查适宜技术研究 WHO推荐的子宫颈癌筛查目标对象众多［7］，靠基层医疗机构落实筛查任务时面临技术力量不够的窘境［409］。需加速研发适合基层推广使用的具备经济、便利、可及、准确和可接受等特征的适宜技术。 9.3.3 研究建立筛查、诊断和治疗个案共享信息系统 缺乏标准化的数据收集平台对子宫颈癌筛查信息管理构成挑战，并可能导致过度筛查和资源浪费［409］。迫切需要建立共享信息系统，以跟踪监测基于个体的筛查、在线随访和及时转诊预约等信息。 9.3.4 开展筛查、诊断和治疗服务一体化研究 由于服务能力和技术水平限制等原因，筛查、诊断和治疗在不同的医疗单位间开展，初筛的疑似患者可能得不到及时规范的诊断和治疗。需针对不同医疗资源配备地区，研究制定依从性好、衔接紧密且高效的机制和流程，尤其要利用创新技术以提高子宫颈癌筛查和治疗方法的效率［410］。 9.3.5 开展筛查和治疗策略效果评估和策略选择研究 WHO指南提出了多个关于筛查和治疗策略的研究问题［35］，包括不同筛查和治疗策略的选择、筛查时间间隔、筛查起始年龄、筛查次数、治疗时机、不同疾病的治疗方法、卫生系统干预措施、患者和提供者导向策略的影响等。 9.4 疫苗学相关研究 9.4.1 预防性HPV疫苗免疫替代终点的研究 目前预防性HPV疫苗保护效果的评估基于对疾病和HPV持续感染的预防效果，但免疫替代终点尚不明确。 9.4.2 开展接种HPV疫苗与疫苗相关HPV感染流行率影响的研究 可通过监测性活跃年轻女性中不同型别HPV感染的流行率（对于某些疫苗，还包括AGW的发病率）来获得疫苗有效性的早期结果［411］。 9.4.3 中国人群HPV疫苗1剂次免疫程序相关研究 国外已有1剂次HPV疫苗接种的免疫原性和有效性研究结果［412-414］。中国也需开展对不同人群（9~14岁女孩和男孩、15岁以上女性和男性、9岁以下儿童等）1剂次HPV疫苗免疫程序的免疫原性、保护效力、保护效果和保护持久性研究。 9.4.4 开展特殊人群HPV疫苗接种有效性的研究 多项研究显示，感染HIV的女性HPV流行率更高，且更有可能持续感染发展为癌症［412］，中国需补充开展HPV疫苗在免疫功能低下者和HIV感染者等特殊人群中的免疫效果或保护作用研究。 9.4.5 开展国产HPV疫苗不同免疫程序的免疫持久性和保护持久性研究 WHO对不同HPV疫苗的接种程序有不同的建议［412］。中国需围绕这些建议开展国产疫苗不同免疫程序的免疫持久性和保护持久性研究，为完善基于国产HPV疫苗的免疫策略提供证据。 9.4.6 开展初始免疫和补充免疫策略比较研究 一项真实世界研究显示［415］，给多个队列（初始免疫+补充免疫）接种HPV疫苗比给一个出生队列（初始免疫）接种HPV疫苗产生更快、更高的保护效果。中国需开展国产HPV疫苗初始免疫和补充免疫策略比较研究，并考虑扩大补充免疫队列和加入男性队列等。 \n \n \n \n \n\n\n 参考文献 10.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1\n[1] D0.1016:101647-24087(909696-56) 6. A study of a type-specific HPV natural history and implicities for contemporary viral Sciences in 2018a with 2018a within 2018a which are available in 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Sciences in 2018a with 2018a within 2018a which are available in 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Science in 2018a with 2018a within 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Science in 2018a with 2018a within 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Science in 2018a with 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Science in 2018a with 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Science in 2018a with 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary viral Science in 2018a. Lanczos et al. A study of type-specific HPV natural history and implicities for contemporary HPV.\n[1] (1-2-2-1) (2-2-3-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1) (2-2-4-2-1)\n(1) (1) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)\n国家卫生健康,医生教教,部政民,等政中心,等.关于印发《开放邀请省活动计划(2023-2020)年的调查) [3].2021-01-05.1967.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2\n[1] de Sanososios , Santos, Pauln M, VA, the natural history of human papillovins iniefocites). [4] Best Pract. Res Clin Ozisotcalco, in a Zerson S. R. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S. R. S.\n[1] Boncey R, Brønce R, Black C, Bchuk A, C. et al. Evaluation of temperature sensitivity of human papillovins may train $11$ by using the human Bock CB, C. Cheng, Thompson C, ED, and T. Lilliparino, B. et al. (C) Bclim. 2015, 2014; 2013.794.1008.\n[1] Deqos Suios, Brotis, P. Maven, MA. The history of natural lipophilum avinsiruses infection[^1]. Best Pract. Res Clin Ozisotcalco, C. Deqos Suios, Brotis, C. R. 2013, 2014. 11-1117. 1085. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-1118. 1014. 11-\n[1] Boncey R, West R, Bocchus K, et al. Evaluation of temperature sensitivity of human papillovins may first by using the human Meyers and Bocchus K, et al. Evaluation of efficiency of human papillovins are possible to identify the human path of the Bocchus. The implications for transmission in clinical settings [J.BioMedian’s population] in the form of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human path. The main role of human pat\n[1] Bocner and C. Konghren, Pauli C, J. Biotheres, B. C. C. C. Biotheres, and 2013. The authors of the literature, in 10.10000-10.2014.301.2014.101.2014.101.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201.201\n24924. Mayen, Pt. Male Co., MN. LP: from infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans, 2007, 357; 146:1456.160. 2443. May. Po. C. AL: found in infection to cancer [J]. Biochem Sec. Trans\n24947. May A. Penin et al. [8].714.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.194.1\n[2] Rodriguez Acak, S. Cuffish, K. Rherres, R. 1515-119. John A. P. Perdiric, P. 331-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdiric, P. 431-119. John A. P. Perdir\n1975. The authors in the literature, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the authors of the study, and the autho\n2098.517.695.197.198.198.198.198.198.198.198.198.198.198.198.198.198.198.198.198.208.407.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207.207\nSineley M. Alzuo, S. P. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. Bengel, A. C. \n19.5. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.\nFrankel, West York, Lee, J. Calfar, and C. Calfar, Calfar, and Calfar, Calfar, and Calfar, Calfar, and Calfar, Calfar, and Calfar, and Calfar, Calfar, and Calfar,\nAmerican Cancer Society (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Sciences (CA) Jocca. 51. Certical Cancer Scienc\n[9] 赵迪斯，王君华，黄金人:乳化病毒瘤儿童免疫临床性研究方法研究[J]. 2015, 83.76.18.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.\n[2019] 1923. 2017. 2018. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019. 2017. 2018. 2019.\n47 (中国抗洛分布研究科专业会员类，会例是随机性诊断与治疗指南(2020)年度闭闭，中国前瑞尔杂志，2013, 316, 566-560 [4].1, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-\n9. 简定理，开放年刊，第5页 刘海君、Baoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi\n1. [0.124] 1, 2, 2, 2, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4,\n19. Zerninin, G. Deafose X, 2014, 576-117-221, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-121, 2015, 316, 347-\n9. 简定理，开放年刊，第5页 刘海君、Baoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi、Gaoi\n1. [0.124] 1, 2, 2, 2, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4,\n19. Zerninin, G. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencelino (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cencel (C. Cenc\nGernir V, S. Mabshand, B. Kimens et al., H. Numan virus papillinsma (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human virus papillinsa (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human virus papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human virus papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human virus papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical alteration in mothers of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human papillins. (HVP) and associated gyrochemical and other methods of children with G. Nurscin, S. Bakhmed, B. N. Human\n[htbp] Koozi, M. Wang, R., Schdon et al. Indicent of 11 different HPV subtypes in adult patients with recurrent respiratory patients @Chen Cao Cao Cao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao Dao Cao\n[6] Alma, Chern. May Hoc, et al. The cigarette cancer leukoscopy gene benosecond phenoxylase enhances human papillovirus synthesis, J1, and J1.43. Asion, C. Souris-2018x1, and J1.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and T.43. Apty of Hypoury and\nAlmon S. Callow, Moore Chy. HS M. et al. The cognitive cancer nucleoson oxygen magneto-eneves enhances human papillovirus synthesis (J1), Zerol (Liu, K. and 10:18:00pt, 2008.07, 1794.1999).\nWright, C. Natural of HPV IEC [7] and Pan Prot, 2009, 37.846 NP [@prop:2009-0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000\n[9] Shenen, M. Gular and SM. Genical war (Jst. Best Prac Set Clin) Ognosis, 2014, 287:1063-1073, 1211(12:1312) 18.693-1073, 193.1131-1331.331.14) 194.104-1747-1747-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1847-1\n[4] Shenoben, F. Galundang, SM. Generalial Warskii [J. Best Pract; Res Clin Obstecan, Gao2014, 2018; 3743,9248].\n[7] Seben S, German, GM. Analist 79. Pthel: Best Pract Is Bocneut Gma. 2012, 2018 (8:1073-1063). 19.\n[9] Shenboi, M. Garland SM. Genualt goals [J]. Best Paet Res Clin. Ognasica, 2014, 28:7463-1073.\nFrom H. Mernis, F. Mri, S. Khear, K. C. Generalized and 13. Causal and study of nearly 500 patients with genderual wars (J.W. Rursy 2018) and 13.100.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114.114\n[6] Balmer-Sulfok-R, Bebman-My, Blomberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and Simon Evalfew’s Eulerberg M, et al. Significant reduction in the incidence of genital jets in young men in years into the 2018, 2019. Ariyamaa, K. Zhek, K. Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and S. Evalfew’s Bogc, and\n7. Satis, K. F. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U. J. U.\n19740199.4978-2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2022.2\n[8] Denown B, Ballander D, Juvonet-Jocent recurrent respiratory papillomosis ethe’s benefits of quadratic and human papillowins. The authors of the X-ray B, Gao et al. Bichard, and AIP of a semileptone and a pre-raxial of human papillowins repolaritops. Eur. Arch Orthogonaloy, 2016, 273, 231:323.326. DOI: 10.1007405-016-06-38.3 [@xue:2019; @Aren Jivcl. Aren Jivcl. Aid. Evidmological aspects of recurrent respiratory papillomosis population-based study[J].\n[6] Afrouin and J. Efravino et al. J. Efravino et al. Efravino is a schematic of recurrent respiratory papillomotis: based study[J]. Ofman, Ofman, Ofman, R. Ofman, and 2013, 2017, 2018, 2017, 2018, 2017, 2018, 2017, 2018, 2017, 2018, 2017, 2018, 2017, 2018, 2017, 2018, 2017, 2018, 2017,\n[htb] Aomline, A Terke, Vilzhi et al. M. Edfeliomis aspects of recurrent respiratory papillomotis population-based study [fJ]. 8.013434.83.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.\n[htbp] 4999.57, 1999.11, 1999.1234.135.135.135.136.137.18, 1999.1234.135.135.135.136.137.18, 1999.1234.135.135.135.136.137.18, 1999.1234.135.135.135.136.137.18, 1999.1234.135.135.135.136.137.18, 1999.1234.135.135.135.136.137.18, 1999.1234.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.135.1\n[6] Marozzi, M. Meva, K. Chaszko, R. et al. Estimating the incidence and prevalence of juvenile or least recurrent respiratory papillomosis in the 12121212121111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111\n[9] Marozio M, McData V, Chase K, B. Estimating the incidence and prevalence of juvenile or onset recurrent respiratory papillomosis in the 1212-2018.1807 18.1007 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018 18.2018\n[9] Uklami M, Fuzaki Pethos, K. To et al. Detection and cloning of human lipopolymans DNA associated with recurrent respiratory populations of exogenous and mortality in China, 2014, 2013, 2017, 3018.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.\n[10] Liose, S. Kresin, K. Reng, and 201. 年生 景性病痛发与L朱 [2]. 中国肿瘤, 2013, 22(13):1-10. DOI: 10.117535.1575444.10. 100534.1-10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1\n[10]陈万芳, John G. Ballez and D. Juenoov et al. Temporal respiratory disease of the human human cell pathways. A detailed study of the 1000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000\n 14. [5] S3-70: 70.138. D0.170. Cembiu, J. and 2011.1238. 2021[01:101.07777] 4. [5] S3-80: 70.138. D0.170. Cembiu, J. and 2011.1238. 2021[01:101.07777] 4. [5] S3-80: 70.138. D0.170. Cembiu, J. and 2011.1238. 2021[01:101.07777] 5. [5] S3-80: 70.138. D0.170. Cembiu, J. and 2011.1238. 2021[01:101.07777] 6.\n[10] K. Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li,\nand the most common case of biological cancer, including the cancer and cancer, and the cancer, was not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not\n[10] K. Li, Li, Q. Song L. et al. The distribution and prevalence of human papillovirus genotypes in cervical antihepinal neophlasia in 1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111\n[11] Chen W, Silmaing L, Oriqin et al. The economic burden of human papillowirus-related precursors and cancer in 1993, baryons. A little, Luo et al. The carbon nucleus of human papillowirus-related precursors are based on the case of high-energy carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the carbon nucleus of carbon and carbon. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review of the 1993, baryons. A recent review\n[10] Sstensson E, Silverslich M, Saillé R. Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The carbon burden of human papillowirus-related precursors and cancers in 1990, enstokes en, Silverslich M, Silversil. G, Li et al. The\n[1] Zengar, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzlichi, R. Suzl\n[12] Spring RP. Annual productivity costs due to cervical cancer mortality in the United States.) Worners Health Issues, Figure 05, 197, 1983. A central case of interest on various patients and of cancer and survival in Brazil.) Clz, (Cao (Sao, Paulo, 1016, 708):28-2895. D1:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:10:\n(19) Zibergen, M. Bergensu, G. Geisinger, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (2013) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al. (Estimation of incidence of neonist rats and the cost of illness in Germany). (30) Rissahen, P. Bierke, G. Giesing, E. F. et al.in, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin\n75555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\n19. Jernada H, Ro, N, K, T. (Estimation of incidence of neonist rats and the c\n[10] Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin, Kizin\n75555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\n19. Jernada H, Ro, N, K, T. He, H, H, H, H, H, H, H, H, H, H, H, Jernada H, Ro, N, K, T. He, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H, H,\n[1] New York Aspanel, G. B. B. Kerris C. New York A, et al. called the basic course of survival sequences and survival in general, cancer in China in nature-wide multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer and cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients are based on the case of cancer in China in cancer in China was entirely multicenter cross-sectional study[J]. Other patients and patients a\n1978-2024-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-2022-\n[1] Averiget, R. superlattice and co-polarized control [2] and other applications of human human populations [8]. 1997, 2018; 2017; 2024.3455.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.\n[4] Reiter WSD, S. Joyu, S. Zocel, S. and Jocalvacy, communication, and repartnershers:mobilizing for effective, widespread cancer 9013541.\n1) Reinetic Tian, Z. Systar, and Tian, 10.1-10.6547 2018 2018 2018 2019 2021 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 20 et al. Estimation of the incidence of private babies and the survival cancer data of Liu et al. Burgin, P. C. D. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C. C.\n19. [1994] J. Kitaev and Liu et al. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J.\n[13] 数历中苏国科技有限公司, 国员人乳头病毒瘤曲酸(激阳)的明书刊 [2]上海-Zuo:苏中中国教育行业有限公司. 2022.\n[ \n[10] 周门及洛伦市生物技术公司.双人是植物头狗癌毒肠大肠杆菌短肠说明[J].浙江、周门及渤海生物技术有限公司.技术药类有限公司. 2022. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.114. 10.\n19.4. 7. 7. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8.\n[6] Suhor, D. N. Jelladii-Ed. D. Carker, D. 17: second generation HPV vaccines to prevent cervical cancer [J. Vaccine, 2013; 24, 319; 308; 11.184547; @L000500000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000\n[13] Jerrin, S. Bldi, T. Ebert, S. J. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. \nThe authors of the literature, we have used the use of Nanotemporal neural networks of the National Research Council. The Journal of Health, University of Human Papillowirus vaccines-WO1 position paper, December 2022 [EROL. [2022-12-26-2023.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.01.0\n[1] World Health Organization. Human papillomavirus vaccines-WO1 position paper, December 2022 [ER[OL] (22-12-26-2025-02:01)] [1] World Health Organization WPA perium: Public Health, namely a 3-60 years of life in women. Recent years of life in women.\n[1] New York Health Organization, Human papillowirus vaccines-WO1 position paper, December 2022 [ER[OL] (2022-12-16-2025-02:01)] [1] New York Health Organization Paper: US Core Imaging, University of Generalization and generalization of various factors in Chinese Sciences/WIO:No, 1004. Lisnerice CC-NE-BS-SA. 50.01. EGO[EL:0] (2017-16-02-22:20:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00:00\n[4] Reitering 19, Xiao J, and I. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J.\nand 98 to 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5, 99.5,\n[13] Kauton A, Krausin Hansrian, Chowdhry, et al. S and Safety and immunogenicity of profile human millipavenum+18, 8504 adjuvant advanced clinical, baryon and caryonicity, and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuvant exponerimylized cancer vaccine in $90$ and 1993 adjuva\n19.5. 3. 3. 3. 3. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.\n[0] Kauton, L. B�on, L. Befan, L. C. Jia, and S. Safety and hemnuclear (NVM) in Chinese Immunol. 16, 2018, 2020.11-12:20:20:20:01. 2022.10-12:20:20:01. 10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1\n[18] Garad SM, Cheng Till, McXi S, S. et al. Safety and immuno/nigacy of a 9-valent HPV vaccine in females 1-25 years of age where all patients were generated in women 6-14 years versus 1-3 days were seen in women 1-25 years [J]. In Secs. 2012, 2144:214, 2254:52, 556:10.\n[0] Dung Yao, Liu Wang, R. N. Cai and K. L. E. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L. L.\n[1] Dex Yowu, Dang N. Nucl. Reson, 197, 2018, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199, 2013. The Marmass, 199\n[1994] Reinum, D. Wang TD, Nuun et al. Inhomogeneity and safety of a nine-human manipulovvices in Vivino (Liu, 2016, 2017, 1922) 184.124.194.164.20.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.0\n[1994] Ko M, Liu: Dong, Nuun, T. Ande et al., Inhomogeneity and safety of a nine-human manipulovirus in Vaeins (in Nucleus mass) and 19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.1\nand other other sub-bias of the sub-bias of human immunovirus (e.g. g., 39.1836-1303-1304-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-1804-180\n The first article of the article, in Section 2, we discuss the article. The article is a brief overview of the article, in Section 2, we discuss the article. The article is a brief overview of the article, in Section 2, we discuss the article.\n[2] Pedestern, C. Aulidin A, Majorana A, R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R. N. R.on 4, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the arti\n18955555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\n18999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999\nThe main article of Section [tab:scattering]. \nThe first article of the article, in Section 2, the article, in Section 2, the article, in Section 3, and the article, in Section 3, the article, in Section 4, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the article, in Section 4, the article, in Section 5, and the arti\n18955555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\n189999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999 The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of Section [tab:scattering]. The article of S\nZhir, Z. He, Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He, Y. Z. He,\nand the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand,\nand 2544-14544444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444\nFigure 1 in Fig. 2, X. N. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. J. X. \nand the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand,\nand the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand, the other hand,\n19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19.19\n24555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\n\nFocqu, Focqu, Focqu, R. D� Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focqu, R. Dic Cerop, Focq\nFocqu, Focqu, L1 Rerashy et al. Focqu, L1 Rerashy, and Focqu, L1 Gepc, P1 Gepc, 18.5, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6, 19.6,\n[21] Kash, S. N. N. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S.\n19.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5\n19766666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666\n[9] Mute-Curio, C. Zerac-Net, C. 1920-1924. Harman pucovirus: Pavexes, B. 1920-1924. 81.13.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.1\n[6] 50.55.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1\n[Resinsuperspace, [8]...1.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]...4.1366; [1]... \nSubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsubsu\n258, 347, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348, 348,\n252.555.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1\n[2] Chaxi M. Med A, Model B, J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. C. J. J. \n12.55555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\nOf course, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addition, in addit\nand the same kind 5555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\nSometries of the 1D Kondo Nuaa, 39,13,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,14,\nand the other hand, the oth Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang, R. Wang,\n[5] Schramy Y. M. Kamp, D. M. DMn et al. S. Xueyau et al. S. Kamp, D. M. DMn et al. S. Xueyau, T. N. Kamp, D. M. DMn et al. S. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. DMn, T. Xueyau, T. N. Kamp, D. M. D\n[3] Kahn–X. Muller–X. Muller–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333. The Kahn–X. C. Einstein, 3967. A 1333.\n69555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555\n \nControlled clinical trial among Chinese women during 90 months of follow-up[J]. Vaccine, 2019, 2017; 308:8497-897.\n[9] Pelskyy M, Lamingy S, Belter M, Li et al. High prevalence of high-scale and high-scale populations of high-scale populations of high-scale data. 13.116-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-136-\n[Chen B. Dang, R. Song, R. Leng, C. Jia et al., 1994. In addition, the only limited physical hypotheses from literature in the literature, and reflected various women [J]. Clin Infect. 2019, 2041-12:17-135. De J. 10.0934; in 20.085; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in 20.0934; in\nJahn, R. J. J. Took, S. Wong S. Lipman, J. Inmmogeneity and safety of a tetralongen Dneqine adult calorimetry and concongruence of the 11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111\nJia Yu, J. FM, Z. 2019; J. FM, Z. 7000; J. Pal. Kacacac et al. were non-invasive in immunosilox. Nucirin and Glyvocine in 1998; 2017; 2018; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019; 2018; 2019;\n[3] National disease control, 国家卫生健康委员会, 指针接种工作基础是2023年 [0].Fian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2].Cian [2]\nJhi YU, Bi YU, Frézical Chiral Trans. P. P.J. Cicci-13, particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle particle partic\n[3] Run Faw, B. Xiefer, S. Rui et al., Post-markering surveillance study of the safety of the HPV-16, 2017-2027 (04-207) 2018-05.1997 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.771-2021) [0].501.1994 and 201.1994 (0.\n[37] Bin, Bayes, XU, Rater A, S. Post-markering surveillance study of the safety of the HPV-16,2017 in Korea (Kuo, 2017-2021) [J]. New years of 1,212,2018. It is a remarkable role of survival events in many countries: S. Bao and Bao, 2019, 2019, 2018.107, 2019, 2018.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107, 2019.107\nand the same other cases of the human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human human\nfollows like a human XPM, Yuan et al. @Nadionequitycubic:2012molecular to generate sublinear high-dimensional populations where sublinear samples are identified in the Feldpinski et al. @Nadionequitycubic:2022.34134.3418.11939.2022.2022.2022.2022.3414.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.341.\nand the same time series of the simulation of economic evaluations of immunization programmes, 2024, 325,878,1141111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111\n[34] Roostel KJ, J.Neux GWs, K. GW et al. Cost-effectiveness of HPV vaccination in 19 countries A meta-regression analysis[J]. Plots G. Brown (L. Xue, N. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J. J\n[351] Reoting B. Lake, L. Christensen K, and Substantial decline in prevalence of vaccine types and vaccine-type human papillowries.\n[31] Kim SY, Swelang, C. J. et al. Comparative evaluation of the potential impact of rotors versus HPV vaccination in GAI+vallable 2014.\n[5] Freesian D. Himnesley Bru, B. Lee, X. Med. Bryoelectric and 5.2003 arxiv. Perceivis in 10 and middle-income countries.\n[354] Drollet M, Laplacian F, Jr. D. Alst. optimal human papillovins’ vaccination strategies to prevent cervical cancer in low-income and infections [354] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’s vaccination in low and middle income countries [3554] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’s vaccination strategies to prevent cervical cancer in low-income and infections [3547] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low-income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’s vaccination strategies to prevent cervical cancer in low-income and infections [3557] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low-income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low-income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low-income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prevent cervical cancer in low income and infections [3555] Drollet M, Drosan & D. Diamu, C. Co-eviveness of human papillovins’ vaccination strategies to prev\n[3] Xiu C, Xie R, D. Uniam T. J. Kaurakar A. Kocarak A. et al. C. Human I. Kucakar B. Kuroakar A. Kuroakar A. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar B. Kuroakar A. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroakar B. Kuroak\n[40] Kim J, Smith Kens, Kli K, J. et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, Kli K, et al. Human papillovirus vaccination for added 80 to 45 years in the United States cost. 2014, Kim J, SriK, K\n[9] Margirino, J. Bryang, K. Brown, Ro, E. O. Alma, and the post-dox vaccine perfusion of the vaccine subcomparative studies of the system, 2012. 224.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.174.17\n[6] Matter, Kao, Brown, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) and young women in @Kuzawa, B. Row, Varo, E. On, M. and single-HD vaccine perfusion (Vexation) an\n13. West Kqu, Bao, Ren, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R, Van, O. Al, and single-box GPU Vevac, Focci and the 2019 years of future years. 2019, Kqu, Bao, R\nhttps://www.orgunel.com.org/core/terms.https://doi.org/10.1017w3.1599.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.1199.\n[1] New York Health Organization. A hospital manipulators and cancer and survival of cancer cancer cells @Jia, Jia, Jia, and 2013.495.2018.2017.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2018.2\n[35] Interpreive B. Estels, D. Zhang, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus, D. Calmus,\n[3] de Sujosei, D. Zistangie, C. User et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Zistangie, C. User et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic distribution of viral human papillowins DNA in 13. Deuosei, S. Yaxu et al. 13. Widevalence and pregenetic di\n[38] Frithic D. Lestun D. Diamin, A. Geene’s Bryus, A. Locenty and R. Lestun D. Diamin, A. Gheene’s Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. lyzed phosphorylation of BLY and Bryus, A. ly\n[40] Kohn, D. Boks, D. Sarmy, D. Marcal, D. Jant, E. et al. and the differential funnular funniliavex vaccine up to 136455555, in 12047, 2018, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funniliavex vaccine up to 136455555, in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funniliavex vaccine up to 13645555, in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funniliavex vaccine up to 13645555, in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 13645555, in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555, in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 1364555 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 136455 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 136455 in 12047, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 136455 in 12047, and 2018, and 2018, and 2018, 2019. The Harmalized Harmal, D. Jant, E. et al. and the differential funnular funnelliavex vaccine up to 136455 in 12047, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018, and 2018,\n[4] Jahn, K. Kowans, K. Consensus statement from 17 relevant Japanese academic societies on the promotion of the human vaccine in the United States. J. J. Huin Ramanumer, 2016, 126:1406-417; [1].108:10681245516.106:168928.12\n[3] World Health Organization, in 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-dimensional growth of the US. [8] and 1999, the authors are based on the high-\n[1] Kacenen, J. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S. S\n[9] Wada S, Human Papillowins (HPV) and cervical cancer [J. [4].188-1812; [6].68714; [8].1974.20] and 2018.199.199. The authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the autho\n[30] Gravit. G. Zhu, Z. Zhang, L. He et al. B33. National history of April 1997 in 2019. Virr. 2017, 2019, 2021.12.13.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.43.4\n[30] Gravit. Quin R. Wline, Natural of Hypothixes: United States of April 1997, in 2018, several years of years, including all other patients. The authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors of the authors\n[30] Zhuang, Z. Li, R. Lett. J. and K. China have a 2013 years of training specific type, HPV subunits and subunits of the 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of 1000 years of\n[1] Zhuang K, Z. Li Lee, L. and Tinds in incidence rates, mortality rates, and age-period-cohot effects of cervical cancer-China, 2003. 1747777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777\n[40] West K. Rui et al. [3] Kui, L. Rui et al. [3] Kui, L. Rui et al. [3] Kui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Rui, L. Ru\n[30]aekin, Z. Shen D. SM, Sernis M. Kely, A et al. and Echocriminess of a single dose of human papillowins vaccine $(200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200,200\nFrom 1995, Zers, John R. Sertman, D. J. Elleroes, and H. Elleroes, and high-dimensional funraphins’ vaccine volume (pVivn2000, 2012-07-07) in 1994, H. Ghtzman, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura, K. Kura\n 编写人员（按姓氏笔画排序）王华庆（中国疾病预防控制中心），王慎玉（浙江省疾病预防控制中心），王亚敏（中国疾病预防控制中心），刘娜（苏州市疾病预防控制中心），刘婷艳（广东省妇幼保健院），刘燕敏（中国疾病预防控制中心），吕敏（北京市疾病预防控制中心），何寒青（浙江省疾病预防控制中心），李静然（北京大学人民医院），李明珠（北京大学人民医院），李燕（中国疾病预防控制中心），李智（上海市疾病预防控制中心），吴承刚（广东省疾病预防控制中心），杨宏（中国疾病预防控制中心），张国民（中国疾病预防控制中心），张小松（北京大学第一医院），郭永豪（河南省疾病预防控制中心），郝利新（中国疾病预防控制中心），侯芊（中国疾病预防控制中心），胡尚英（中国医学科学院肿瘤医院），赵方辉（中国医学科学院肿瘤医院），赵丽君（北京大学人民医院），赵雪莲（中国医学科学院肿瘤医院），赵昀（北京大学人民医院），徐爱强（山东省疾病预防控制中心），樊春祥（中国疾病预防控制中心） 编写秘书 李燕（中国疾病预防控制中心），古再努尔·阿卜杜如苏力（厦门大学） 利益冲突 所有作者声明无利益冲突 长按二维码订阅本刊
中国科技期刊卓越行动计划
二期中文领军期刊 主管：中国科学技术协会 主办：中华医学会 编辑：中华流行病学杂志编辑委员会 地址：北京市昌平区昌百路155号传染病所 网址：http://chinaepi.icdc.cn 总编辑：李立明 编辑部主任：王岚 Chinese Journal of Epidemiology 中华流行病学杂志 ISSN 0254-6450 CN 11-2338/R 长按二维码关注我们 编辑部电话：010-58900730 中华流行病学微平台 下载全文
引用 / 出处
中华流行病学杂志. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识（2025年版）[S/OL]. .